Journal article icon

Journal article

Metformin: the safest hypoglycaemic agent in chronic kidney disease?

Abstract:

Metformin is the first-line oral agent in the treatment of type 2 diabetes and has many established benefits, including the reduction of macrovascular complications of diabetes. Its prescription in patients with renal impairment is limited by concerns relating to the theoretical risk of lactic acidosis, a fear which is perpetuated by numerous case reports in which it is implicated. Critical review of this literature calls into question the validity of these claims, with metformin usually acti...

Expand abstract

Actions


Access Document


Publisher copy:
10.1159/000323739

Authors


Journal:
Nephron. Clinical practice
Volume:
118
Issue:
4
Pages:
c380-c383
Publication date:
2011-01-01
DOI:
EISSN:
1660-2110
ISSN:
1660-8151
URN:
uuid:7329031b-561c-493e-b113-5e6c11880a9e
Source identifiers:
485113
Local pid:
pubs:485113

Terms of use


Metrics


Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP